Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Whole Brain Radiotherapy in Combination With Gefitinib (Iressa) or Temozolomide (Temodal) for Brain Metastases From Non-Small Lung Cancer (NSCLC) A Randomized Phase II Trial

NCT00238251 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00238251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00238251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Whole Brain Radiotherapy in Combination With Gefitinib (Iressa) or Temozolomide (Temodal) for Brain Metastases From Non-Small Lung Cancer (NSCLC) A Randomized Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2005
Completion date
November 30, 2010
Enrollment
59 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, metastatic cancer